Skip to content

Denali Therapeutics Inc. DNLI Finance Lease Liability, Current

Finance Lease Liability, Current at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$6M+18.9%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.24M-31.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s finance lease liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s finance lease liability, current?
Denali Therapeutics Inc. (DNLI) reported finance lease liability, current of $90K in Q1 2026.
What does finance lease liability, current mean?
Finance lease liabilities (current) represent the portion of lease obligations that are due to be paid within the next twelve months. These obligations arise from long-term contracts where the company effectively controls the leased asset. This metric is critical for assessing near-term liquidity and cash flow requirements.